EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Steffen Flindt Nielsen iD, Camilla Lundgreen Duus iD, Niels Henrik Buus iD, Jesper Nørgaard Bech iD, Frank Holden Mose iD

JMIR Research Protocols · 2024

DOI: 10.2196/56067 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2024. Verfasst von Steffen Flindt Nielsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic in Nephrology and Hypertension, Gødstrup Hospital and Aarhus University, Herning, Denmark. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Cross-Over Studies, Diabetes Mellitus, Type 2, Glucosides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) have revolutionized the treatment of type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD), reducing the risk of cardiovascular and renal end points by up to 40%. The underlying mechanisms are not fully understood.

Objective

The study aims to examine the effects of empagliflozin versus placebo on renal hemodynamics, sodium balance, vascular function, and markers of the innate immune system in patients with DM2, DM2 and CKD, and nondiabetic CKD.

Methods

We conducted 3 double-blind, crossover, randomized controlled trials, each with identical study protocols but different study populations. We included patients with DM2 and preserved kidney function (estimated glomerular filtration rate >60 mL/min/1.73 m2), DM2 and CKD, and nondiabetic CKD (both with estimated glomerular filtration rate 20-60 mL/min/1.73 m2). Each participant was randomly assigned to 4 weeks of treatment with either 10 mg of empagliflozin once daily or a matching placebo. After a wash-out period of at least 2 weeks, participants were crossed over to the opposite treatment. End points were measured at the end of each treatment period. The primary end point was renal blood flow measured with 82Rubidium positron emission tomography–computed tomography (82Rb-PET/CT). Secondary end points include glomerular filtration rate measured with 99mTechnetium-diethylene-triamine-pentaacetate (99mTc-DTPA) clearance, vascular function assessed by forearm venous occlusion strain gauge plethysmography, measurements of the nitric oxide (NO) system, water and sodium excretion, body composition measurements, and markers of the complement immune system.

Results

Recruitment began in April 2021 and was completed in September 2022. Examinations were completed by December 2022. In total, 49 participants completed the project: 16 participants in the DM2 and preserved kidney function study, 17 participants in the DM2 and CKD study, and 16 participants in the nondiabetic CKD study. Data analysis is ongoing. Results are yet to be published.

Conclusions

This paper describes the rationale, design, and methods used in a project consisting of 3 double-blind, crossover, randomized controlled trials examining the effects of empagliflozin versus placebo in patients with DM2 with and without CKD and patients with nondiabetic CKD, respectively. Trial Registration EU Clinical Trials Register 2019-004303-12; https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004303-12, EU Clinical Trials Register 2019-004447-80; https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004447-80, EU Clinical Trials Register 2019-004467-50; https://www.clinicaltrialsregister.eu/ctr-search/search?query=and+2019-004467-50 International Registered Report Identifier (IRRID) DERR1-10.2196/56067

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicCross-Over StudiesDiabetes Mellitus, Type 2GlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsHumansDouble-Blind MethodMaleMiddle AgedFemaleAdultAgedGlomerular Filtration RateRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

CKDCVDDM2DenmarkRCTSGLT2iT2DMblood flowcardiovascular diseasechronic kidney diseasediabetes mellitus type 2empagliflozinplaceborandomized controlled trialrecruitment

Substanzen

empagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • University Clinic in Nephrology and Hypertension, Gødstrup Hospital and Aarhus University, Herning, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose

Zitieren

APA

Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024). Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project). JMIR Research Protocols. https://doi.org/10.2196/56067

Vancouver

Nielsen SF, Duus CL, Buus NH, Bech JN, Mose FH. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project). JMIR Research Protocols. 2024. doi:10.2196/56067

BibTeX
@article{Nielsen2024,
  author = {Nielsen, Steffen Flindt and Duus, Camilla Lundgreen and Buus, Niels Henrik and Bech, Jesper Nørgaard and Mose, Frank Holden},
  title = {Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)},
  journal = {JMIR Research Protocols},
  year = {2024},
  doi = {10.2196/56067}
}
Kostenlos starten →